Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Paola A Griffiths 0179260
resgov@swansea.ac.uk


Kathie Wareham kathie.wareham@wales.nhs.uk


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Circulating Ghrelin as a Biomarker for Dementia

Circulating Ghrelin as a Biomarker for Dementia

Recruiting

Open to: ALL

Age: 60.0 - N/A

Medical Conditions

Dementia


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive impairment. It will focus on validating pilot data generated following the analysis of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS project ID: 250933). In addition to the advantages of study replication we will extend the analysis to include two further patient groups that are associated with cognitive impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This study will increase confidence in the replication of our findings.

This will be a cross-sectional study using peripheral venous blood.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2022 Sep 2024

INTERVENTIONAL

Intervention Type : DIAGNOSTIC_TEST
Intervention Description : Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Intervention Arm Group : Alzheimer's disease;Dementia with Lewy Bodies;Healthy control;Parkinson's disease;Parkinson's disease dementia;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Swansea University
    Swansea
    sa2 8pp

Paola A Griffiths 0179260
resgov@swansea.ac.uk


Kathie Wareham kathie.wareham@wales.nhs.uk



The study is sponsored by Swansea University and is in collaboration with Newcastle University.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05381090
Last updated 25 October 2023

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.